MedTrace Logo

Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)

NCT07185841 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2025-09-25

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of Oral HX9428 tablets in patients with wet age-related macular degeneration(wAMD)

Conditions

  • Wet Age-related Macular Degeneration (AMD)

Interventions

DRUG

HX9428 tablet

Subjects will receive HX9428 orally every day. The total treatment period is tentatively set at 25 weeks..

Sponsors & Collaborators

  • Fujian Haixi Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hong Dai · Beijing Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2028-07-01
Completion
2029-01-07

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07185841 on ClinicalTrials.gov